Drug-induced parkinsonism in the elderly

Future Neurology

Volumn 2, Issue 3, 2007, Pages 307-316

  Chou, Kelvin L ^a   Friedman, Joseph H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Antipsychotics; Drug induced parkinsonism; Elderly; Parkinsonism

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; CISAPRIDE; CLOZAPINE; DOMPERIDONE; FLUNARIZINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; MESORIDAZINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; PROCHLORPERAZINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; VERAPAMIL; ZIPRASIDONE;

AGED; AGING; AGRANULOCYTOSIS; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE METABOLISM; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; ELDERLY CARE; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; HYPOXIA; INFECTION; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS; MOTOR DYSFUNCTION; NAUSEA; PARKINSONISM; PHENOMENOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW; VESTIBULAR DISORDER;

EID: 34249340483     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.3.307     Document Type: Review

References (107)

1. Pall HS, Williams AC: Extrapyramidal disturbances caused by inappropriate prescribing. Br. Med. J. (Clin. Res. Ed.) 295(6589), 30-31 (1987).
2. Trenkwalder C, Schwarz J, Gebhard J et al.: Starnberg trial on epidemiology of Parkinsonism, and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch. Neurol. 52(10), 1017-1022 (1995).
3. Barbosa MT, Caramelli P, Maia DP et al.: Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov. Disord. 21(6), 800-808 (2006).
4. Morgante L, Rocca WA, Di Rosa AE et al.: Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) group. Neurology 42(10), 1901-1907 (1992).
5. Benito-Leon J, Bermejo-Pareja F, Rodriguez J: Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov. Disord. 18(3), 267-274 (2003).
6. Bennett DA, Beckett LA, Murray AM et al.: Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med. 334(2), 71-76 (1996).
7. Parkinson J: An Essay on the Shaking Palsy. Sherwood, Neely, and Jones, London, UK (1817).
8. Lance JW, Schwab RS, Peterson EA: Action tremor and the cogwheel phenomenon in Parkinson's disease. Brain 86, 95-110 (1963).
9. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 17(5), 427-442 (1967).
10. Hunker CJ, Abbs JH: Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue, and index finger. Mov. Disord. 5(1), 71-77 (1990).
11. Litvan I, Bhatia KP, Burn DJ et al.: Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18(5), 467-486 (2003).
12. Galvin JE, Pollack J, Morris JC: Clinical phenotype of Parkinson disease dementia. Neurology 67(9), 1605-1611 (2006).
13. Hung SW, Lang AE: Differential diagnosis of Parkinson's disease. In: Parkinson's Disease. Ebadi M, Pfeiffer RF (Eds). CRC Press, FL, USA 557-568 (2005).
14. McKeith IG, Dickson DW, Lowe J et al.: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12), 1863-1872 (2005).
15. Allan LM, Ballard CG, Burn DJ, Kenny RA: Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. J. Am. Geriatr. Soc. 53(10), 1681-1687 (2005).
16. Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 175, 1054-1060 (1961).
17. Caligiuri MP, Lacro JP, Jeste DV: Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J. Clin. Psychopharmacol. 19(4), 322-328 (1999).
18. Caligiuri MP, Lohr JB: Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients. J. Neuropsychiatry Clin. Neurosci. 9(4), 562-567 (1997).
19. Dean CE, Kuskowski MA, Caligiuri MP: Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. J. Clin. Psychopharmacol. 26(6), 560-565 (2006).
20. Marsden CD, Mindham RHS, Mackay AVP: Extrapyramidal movement disorders produced by antipsychotic drugs. In: Psychopharmacology and Treatment of Schizophrenia. Bradley PB (Ed.). Oxford University Press, Oxford, UK 340-402 (1986).
21. Caligiuri MP, Rockwell E, Jeste DV: Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication. Am. J. Geriatr. Psychiatry 6(1), 75-82 (1998).
22. Hassin-Baer S, Sirota P, Korczyn AD et al.: Clinical characteristics of neuroleptic-induced parkinsonism. J. Neural Transm. 108(11), 1299-1308 (2001).
23. Manyam BV: Uncommon forms of tremor. In: Movement Disorders. Neurologic Principles and Practice. Watts RL, Koller WC (Eds). McGraw-Hill Companies, NY, USA 459-480 (2004).
24. Hardie RJ, Lees AJ: Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J. Neurol. Neurosurg. Psychiatry 51(6), 850-854 (1988).
25. Tolosa E, Coelho M, Gallardo M: DAT imaging in drug-induced and psychogenic parkinsonism. Mov. Disord. 18(Suppl. 7), S28-S33 (2003).
26. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R: (123I)-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov. Disord. 21(4), 510-514 (2006).
27. Azima H, Ogle W: Effects of largactil in mental syndromes. Can. Med. Assoc. J. 71(2), 116-121 (1954).
28. DiMascio A, Demirgian E: Antiparkinson drug overuse. Psychosomatics 11(6), 596-601 (1970).
29. Kennedy PF, Hershon HI, McGuire RJ: Extrapyramidal disorders after prolonged phenothiazine therapy. Br. J. Psychiatry 118(546), 509-518 (1971).
30. Klawans HL Jr, Bergen D, Bruyn GW: Prolonged drug-induced Parkinsonism. Confin. Neurol. 35(6), 368-377 (1973).
31. Stephen PJ, Williamson J: Drug-induced parkinsonism in the elderly. Lancet 2(8411), 1082-1083 (1984).
32. Negrotti A, Calzetti S: A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov. Disord. 12(1), 107-110 (1997).
33. Fernandez HH, Krupp B, Friedman JH: The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 56(6), 805-807 (2001).
34. Miller LG, Jankovic J: Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch. Intern. Med. 149(11), 2486-2492 (1989).
35. Friedman JH, Fernandez HH, Trieschmann MM: Parkinsonism in a nursing home: underrecognition. J. Geriatr. Psychiatry Neurol. 17(1), 39-41 (2004).
36. Friedman JH, Skeete R, Fernandez HH: Unrecognized parkinsonism in acute care medical patients receiving neurological consultations. J. Gerontol. A Biol. Sci. Med. Sci. 58(1), 94-95 (2003).
37. Caligiuri MR, Jeste DV, Lacro JP: Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 17(5), 363-384 (2000).
38. Guttmacher MS: Phenothiazine treatment in acute schizophrenia; effectiveness: the National Institute Of Mental Health Psychopharmacology Service Center Collaborative Study group. Arch. Gen. Psychiatry 10, 246-261 (1964).
39. Kapur S, Remington G: Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52, 503-517 (2001).
40. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J. Pharmacol. Exp. Ther. 251(1), 238-246 (1989).
41. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
42. Schneider LS, Tariot PN, Dagerman KS et al.: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med. 355(15), 1525-1538 (2006).
43. Rochon PA, Stukel TA, Sykora K et al.: Atypical antipsychotics and parkinsonism. Arch. Intern. Med. 165(16), 1882-1888 (2005).
44. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry 14(3), 191-210 (2006).
45. Breier A, Sutton VK, Feldman PD et al.: Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psychiatry 52(5), 438-445 (2002).
46. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J: Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord. 17(5), 1031-1035 (2002).
47. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55(6), 789-794 (2000).
48. Ford B, Lynch T, Greene P: Risperidone in Parkinson's disease. Lancet 344(8923), 681 (1994).
49. Rich SS, Friedman JH, Ott BR: Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J. Clin. Psychiatry 56(12), 556-559 (1995).
50. Meco G, Alessandri A, Giustini P, Bonifati V: Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov. Disord. 12(4), 610-612 (1997).
51. Leopold NA: Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov. Disord. 15(2), 301-304 (2000).
52. Mohr E, Mendis T, Hildebrand K, De Deyn PP: Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov. Disord. 15(6), 1230-1237 (2000).
53. Meco G, Alessandria A, Bonifati V, Giustini P: Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 343(8909), 1370-1371 (1994).
54. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME: The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 9(4), 594-597 (1997).
55. Friedman JH, Factor SA: Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 15(2), 201-211 (2000).
56. Rosebush PI, Mazurek MF: Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52(4), 782-785 (1999).
57. Wolters EC, Hurwitz TA, Mak E et al.: Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40(5), 832-834 (1990).
58. Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340(10), 757-763 (1999).
59. Pollak P, Tison F, Rascol O et al.: Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry 75(5), 689-695 (2004).
60. Migler BM, Warawa EJ, Malick JB: Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology (Berl.) 112(2-3), 299-307 (1993).
61. Ondo WG, Tintner R, Dat Voung K, Lai D, Ringholz G: Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20(8), 958-963 (2005).
62. Rabey JM, Prokhorov T, Miniovich A, Klein C: The effect of quetiapine in Parkinson's disease (PD) psychotic patients: a double-blind labeled study of three months duration. Mov. Disord. 20(Suppl. 10), S46 (2005).
63. Ballard C, Margallo-Lana M, Juszczak E et al.: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330(7496), 874 (2005).
64. Tariot PN, Schneider L, Katz IR et al.: Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am. J. Geriatr. Psychiatry 14(9), 767-776 (2006).
65. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross MA, Docherty JP: The Expert Consensus Guideline Series. Treatment of dementia and its behavioral disturbances. Postgrad Med. 6-22 (2005).
66. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin. Ther. 22(9), 1068-1084 (2000).
67. Bateman DN, Darling WM, Boys R, Rawlins MD: Extrapyramidal reactions to metoclopramide and prochlorperazine. Q. J. Med. 71(264), 307-311 (1989).
68. Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A: Increased incidence of levodopa therapy following metoclopramide use. JAMA 274(22), 1780-1782 (1995).
69. Ganzini L, Casey DE, Hoffman WF, McCall AL: The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch. Intern. Med. 153(12), 1469-1475 (1993).
70. Barone JA: Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann. Pharmacother. 33(4), 429-440 (1999).
71. Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov. Disord. 12(6), 952-957 (1997).
72. Micheli FE, Pardal MM, Giannaula R et al.: Movement disorders and depression due to flunarizine and cinnarizine. Mov. Disord. 4(2), 139-146 (1989).
73. Marti-Masso JF, Poza JJ: Cinnarizine-induced parkinsonism: ten years later. Mov. Disord. 13(3), 453-456 (1998).
74. Fabiani G, Pastro PC, Froehner C: Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq. Neuropsiquiatr. 62(3B), 784-788 (2004).
75. Chouza C, Scaramelli A, Caamano JL, De Medina O, Aljanati R, Romero S: Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1(8493), 1303-1304 (1986).
76. Gimenez-Roldan S, Mateo D: Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin. Neuropharmacol. 14(2), 156-164 (1991).
77. Micheli F, Pardal MF, Garto M et al.: Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 37(5), 881-884 (1987).
78. Brucke T, Wober C, Podreka I et al.: D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J. Cereb. Blood Flow Metab. 15(3), 513-518 (1995).
79. +-ATPase in catecholamine storage vesicles. Neuropharmacology 38(6), 879-882 (1999).
80. Garcia-Albea E, Jimenez-Jimenez FJ, Ayuso-Peralta L, Cabrera-Valdivia F, Vaquero A, Tejeiro J: Parkinsonism unmasked by verapamil. Clin. Neuropharmacol. 16(3), 263-265 (1993).
81. Padrell MD, Navarro M, Faura CC, Horga JF: Verapamil-induced parkinsonism. Am. J. Med. 99(4), 436 (1995).
82. Dick RS, Barold SS: Diltiazem-induced parkinsonism. Am. J. Med. 87(1), 95-96 (1989).
83. Graham DF, Stewart-Wynne EG: Diltiazem-induced acute parkinsonism. Aust. NZ J. Med. 24(1), 70 (1994).
84. Sempere AP, Duarte J, Cabezas C, Coria F, Claveria LE: Parkinsonism induced by amlodipine. Mov. Disord. 10(1), 115-116 (1995).
85. Teive HA, Germiniani FM, Werneck LC: Parkinsonian syndrome induced by amlodipine: case report. Mov. Disord. 17(4), 833-835 (2002).
86. Mena MA, de Yebenes JG: Drug-induced parkinsonism. Expert Opin. Drug Saf. 5(6), 759-771 (2006).
87. Dotti MT, Federico A: Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov. Disord. 10(2), 233-234 (1995).
88. Malaterre HR, Renou C, Kallee K, Gauthier A: Akinesia and amiodarone therapy. Int. J. Cardiol. 59(1), 107-108 (1997).
89. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann. Neurol. 25(6), 630-632 (1989).
90. Matsui A, Matsuo H, Takanaga H, Sasaki S, Maeda M, Sawada Y: Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. J. Pharmacol. Exp. Ther. 287(2), 725-732 (1998).
91. Marti Masso JF, Marti I, Carrera N, Poza JJ, Lopez de Munain A: Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 60(4), 419-422 (2005).
92. Reversible Parkinsonism linked to trimetazidine (continued). Prescrire Int. 15(84), 136 (2006).
93. Sommet A, Azais-Vuillemin C, Bagheri H, Rascol O, Montastruc JL: Trimetazidine: a new cause for drug-induced parkinsonism? Mov. Disord. 20(8), 1080-1081 (2005).
94. Ghadirian AM, Annable L, Belanger MC, Chouinard G: A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J. Clin. Psychiatry 57(1), 22-28 (1996).
95. Holroyd S, Smith D: Disabling parkinsonism due to lithium: a case report. J. Geriatr. Psychiatry Neurol. 8(2), 118-119 (1995).
96. Lang AE: Lithium and parkinsonism. Ann. Neurol. 15(2), 214 (1984).
97. Muthane UB, Prasad BN, Vasanth A, Satishchandra P: Tardive Parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate. J. Neurol. Sci. 176(1), 78-79 (2000).
98. Jamora D, Lim SH, Pan A, Tan L, Tan EK: Valproate-induced Parkinsonism in epilepsy patients. Mov. Disord. 22(1), 130-133 (2006).
99. Armon C, Shin C, Miller P et al.: Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 47(3), 626-635 (1996).
100. Di Rocco A, Brannan T, Prikhojan A, Yahr MD: Sertraline induced parkinsonism. A case report and an in vivo study of the effect of sertraline on dopamine metabolism. J. Neural Transm. 105(2-3), 247-251 (1998).
101. Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry 57(10), 449-454 (1996).
102. Mendhekar DN, Benuiwal RP, Puri V: Parkinsonism and elevated lactic acid with sertraline. Can. J. Psychiatry 50(5), 301 (2005).
103. Pina Latorre MA, Modrego PJ, Rodilla F, Catalan C, Calvo M: Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J. Clin. Pharm. Ther. 26(2), 111-112 (2001).
104. Richard IH, Maughn A, Kurlan R: Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov. Disord. 14(1), 155-157 (1999).
105. Avorn J, Bohn RL, Mogun H et al.: Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am. J. Med. 99(1), 48-54 (1995).
106. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284(15), 1931-1938 (2000).
107. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484-1491 (2000).